A Common Technical Document is a standardized way to organize information about a medicine or medical device

A Common Technical Document (CTD) is a single, organized file that contains all the scientific, manufacturing, and safety information a company submits when asking a government health agency to approve a drug or medical device. Instead of each country requiring its own separate submission with different formats and organization, the CTD lets a company submit the same document to regulators in the United States, Europe, Japan, and other countries that accept this standard.

The CTD exists because before it was created, pharmaceutical companies had to rewrite and reorganize the same information multiple times — once for the FDA, once for European regulators, once for Japanese regulators, and so on. This wasted time and created opportunities for errors. The CTD format, established in the late 1990s, solved that problem by creating one structure that all major regulators agreed to accept.

You will not interact with a CTD yourself unless you work in pharmaceutical or medical device regulation. But if you take a prescription medication or use a medical device, the approval process that brought it to market involved a CTD somewhere in the chain.

Key Takeaways

  • A Common Technical Document is a standardized file format that companies use to submit drug and device information to government health regulators.
  • The CTD format is accepted by the FDA, European regulators, and health agencies in other countries, so companies can submit once instead of multiple times.
  • The document is organized into five modules: administrative information, summaries, quality data, nonclinical study reports, and clinical study reports.
  • The CTD saves time and reduces errors by using one consistent structure across all countries instead of requiring separate submissions for each regulator.

The five modules that make up a CTD

The CTD is divided into five sections, called modules, each containing a specific type of information. Module 1 holds administrative paperwork — the company name, the drug name, the regulatory history, and letters to the agency. This module is usually customized for each country because different regulators have different forms and requirements.

Modules 2 through 5 are identical across all submissions. Module 2 contains summaries written for regulators who may not be experts in every field — a summary of the chemistry and manufacturing, a summary of the nonclinical (laboratory and animal) studies, and a summary of the clinical (human) studies. Module 3 covers quality: how the drug is made, what the active ingredient is, how it is tested for purity and strength, and how it is stored. Module 4 holds the full reports from every nonclinical study — toxicology tests, animal studies, and laboratory work. Module 5 holds the full reports from every clinical trial in humans.

A CTD for a major drug can be thousands of pages long, organized into dozens of subsections. The standardized structure means a regulator in Japan can find the manufacturing data in the same place as a regulator in the United States, even though they are reading the same document.

Why regulators require this format

Government health agencies like the FDA require the CTD format because it makes their review faster and more consistent. When all the information is in the same place every time, reviewers spend less time hunting for data and more time evaluating whether the drug or device is safe and effective. A reviewer can open a CTD for a heart medication and know exactly where to find the clinical trial results, the manufacturing process, and the safety data.

The standardized format also reduces the chance that important information gets lost or overlooked. Before the CTD, companies sometimes organized information differently in each submission, and regulators sometimes missed details because they were looking in an unexpected place. The CTD eliminates that problem by making the organization predictable.

The format also allows regulators in different countries to share information more easily. If the FDA approves a drug, European regulators can review the same CTD and make their own decision without asking the company to reformat everything. This speeds up approval worldwide and means patients in different countries can access new medicines faster.

How the CTD differs from what you see on a medicine label

The information in a CTD is raw scientific data — the full results of every clinical trial, every manufacturing test, every safety report. The label on a medicine bottle or the package insert that comes with a prescription is a summary written for patients and doctors, created from information in the CTD but much shorter and in plain language.

A CTD might contain 50 clinical trials; the label will mention only the most important results. A CTD will list every adverse event reported during testing; the label will list only the side effects that occurred in a meaningful number of people. The CTD is the complete record that regulators use to make their decision; the label is the practical information that patients and doctors actually need to use the medicine safely.

Who creates and submits a CTD

Pharmaceutical companies and medical device manufacturers create CTDs and submit them to regulatory agencies. Large companies often have entire departments dedicated to assembling CTDs because the document must be accurate, complete, and properly formatted or the regulator will reject it and ask for corrections.

Smaller companies sometimes hire specialized consulting firms that know the CTD format inside and out and can help organize the data correctly. These consultants do not conduct the studies or manufacture the drug — they organize the information that the company has already generated into the CTD structure that regulators require.

Once a company submits a CTD, the regulatory agency assigns reviewers to examine each module. The review process typically takes months or years, depending on the complexity of the drug and whether the company needs to provide additional information.

The CTD in different countries

The CTD format is accepted by the FDA in the United States, the European Medicines Agency (EMA) in Europe, the Pharmaceuticals and Medical Devices Agency (PMDA) in Japan, and health regulators in Canada, Australia, and many other countries. This international acceptance is why the format was created in the first place — to reduce duplication and speed up global approval.

Module 1, the administrative section, does vary by country because each regulator has its own forms and requirements. A company submitting to the FDA will include FDA-specific forms in Module 1; a company submitting to the EMA will include different forms. But Modules 2 through 5 remain identical, so the company does not have to rewrite the scientific data.

Some countries that are not part of the major regulatory bodies may not accept the CTD format and may require their own submission structure. A company seeking approval in a smaller market might need to adapt the CTD into a different format for that country's regulator.

What happens after a CTD is approved

Once a regulator approves a drug or device based on the CTD, the company can manufacture and sell it in that country. The CTD does not end there — it becomes part of the permanent regulatory record. If a safety issue emerges after approval, regulators can refer back to the original CTD to understand what was known at the time of approval and what new information has emerged.

Companies must also update the CTD if they change how they manufacture the drug, add a new indication (a new disease or condition it treats), or conduct additional studies. These updates go through a similar review process, though usually faster than the original approval because the regulator has already reviewed the basic information.

Frequently Asked Questions

Can I look at a CTD for a medicine I take?

CTDs are submitted to government agencies, not published for the public. However, much of the information in a CTD becomes public through the FDA's website or the EMA's website after approval. You can search for a drug name and find summaries of clinical trials, manufacturing information, and approved labeling. The full CTD itself remains with the regulatory agency.

Does every medicine have a CTD?

Most prescription drugs and many medical devices approved in the United States, Europe, or Japan have a CTD. Older drugs approved before the CTD format existed may not have been submitted in this format. Over-the-counter medicines and dietary supplements follow different regulatory pathways and typically do not require a CTD.

What if a company makes a mistake in the CTD?

If a regulator finds an error or missing information during review, they send the company a list of questions or deficiencies. The company must correct the CTD and resubmit it. Major errors can delay approval by months. This is why companies invest in careful review before submitting — mistakes are expensive.

Is the CTD format used for vaccines?

Yes. Vaccines submitted to the FDA, EMA, or other major regulators use the CTD format. The modules are the same, though the content reflects the specific nature of vaccine development — immunogenicity data, efficacy trials, and safety monitoring in large populations.